Transforming growth factor β induced as a novel secreted immune checkpoint counterinhibiting human tumor-associated T cells
Journal for ImmunoTherapy of Cancer · 2026-04 · 14 (4) · e012668
DOI: 10.1136/jitc-2025-012668 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 02.04.2026. Verfasst von Maria Manuela Rosado und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research, Advanced Diagnostic and Technological Innovation Translational Research Functional Departmental Area, Regina Elena Institute,…. Hauptthemen laut MEDLINE: Transforming Growth Factor beta, Colorectal Neoplasms, Liver Neoplasms, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell’Istruzione, dell’Università e della Ricerca, Fondazione Italiana Sclerosi Multipla, Associazione Italiana per la Ricerca sul Cancro.
Abstract (Originalsprache)
Background
We investigated the hypothesis that transforming growth factor β induced (TGFBI), an extracellular matrix protein secreted in the microenvironment of several tumors, can act as a secreted immune checkpoint (sIC) that contributes to the suppression of human antitumor T cell responses. Methods and results Serum TGFBI concentrations, measured by ELISA, were significantly higher in patients with colorectal cancer (CRC) and hepatocellular carcinoma than in healthy individuals and associated with poor overall survival. Strikingly, multiparametric flow cytometry analyses revealed that TGFBI was abundantly expressed by tumor cells or monocytes, and by various lymphoid cell types—including CD4 + or CD8 + T cells (including tissue-resident memory T cells), B cells, and natural killer cells—in patients with cancer. Importantly, ex vivo TGFBI neutralization significantly enhanced CD4 + and CD8 + T cell activation and function. Freshly isolated TGFBI-expressing CD4 + or CD8 + T cells demonstrated a markedly improved capacity to differentiate into functional effector cells—characterized by the acquisition of tissue-homing phenotypes—following TGFBI blockade. These findings suggest that TGFBI can establish an autocrine immunosuppressive loop within T cells, thereby limiting their differentiation and function. These mechanistic observations were further supported by human CRC organoid-based experiments, where TGFBI blockade improved expansion and tumor cell killing by major histocompatibility complex class I-restricted cytotoxic T cells.
Conclusions
Taken together, our data demonstrate that TGFBI acts as a sIC counter-regulating T cell activation, differentiation, and effector function, which can be restored by TGFBI blockade, with broad implications for novel immunotherapy strategies in solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Research, Advanced Diagnostic and Technological Innovation Translational Research Functional Departmental Area, Regina Elena Institute, Roma, Italy.
- Department of Internal Clinical Sciences, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
- Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia, Rome, Italy.
- Department of Paediatric Haematology/Oncology and Cell and Gene Therapy, Bambino Gesu Pediatric Hospital IRCCS, Rome, Italy.
- Department of Clinical Science and Translational Medicine, "Tor Vergata" University of Rome, Rome, Italy.
- Istituto Superiore di Sanità, Rome, Italy.
Förderung
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Fondazione Italiana Sclerosi Multipla
- Associazione Italiana per la Ricerca sul Cancro
- Fondation pour la Recherche Médicale
- Cancer Research UK
Zitieren
APA
Rosado, M. M., Timperi, E., Melaiu, O., Vitale, S., Bachy, S., Grimaldi, A., Corrado, M., Mancini, V., Leonti, G., Conti, F., Cammarata, I., Celardo, I., Kucykowicz, S., Aidoo-Micah, G., Gragera, P., Accapezzato, D., Del Ben, M., D'Oria, V., De Stefanis, C., …, & Barnaba, V. (2026). Transforming growth factor β induced as a novel secreted immune checkpoint counterinhibiting human tumor-associated T cells. Journal for ImmunoTherapy of Cancer, 14(4), e012668. https://doi.org/10.1136/jitc-2025-012668
Vancouver
Rosado MM, Timperi E, Melaiu O, Vitale S, Bachy S, Grimaldi A, et al. Transforming growth factor β induced as a novel secreted immune checkpoint counterinhibiting human tumor-associated T cells. Journal for ImmunoTherapy of Cancer. 2026;14(4):e012668. doi:10.1136/jitc-2025-012668
BibTeX
@article{Rosado2026,
author = {Rosado, Maria Manuela and Timperi, Eleonora and Melaiu, Ombretta and Vitale, Sara and Bachy, Sophie and Grimaldi, Alessio and Corrado, Mariachiara and Mancini, Vanessa and Leonti, Gabriela and Conti, Filippo and Cammarata, Ilenia and Celardo, Ivana and Kucykowicz, Stephanie and Aidoo-Micah, Gloryanne and Gragera, Paula and Accapezzato, Daniele and Del Ben, Maria and D'Oria, Valentina and De Stefanis, Cristiano and Forcina, Laura and Frattaroli, Fabrizio and Picchetto, Andrea and Chiaretti, Massimo and D'Ambrosio, Giancarlo and Giannini, Giuseppe and Belardinilli, Francesca and Scarinci, Andrea and Grazi, Gian Luca and Musarò, Antonio and Maini, Mala K and Fiori, Micol E and Fruci, Doriana and Hennino, Anca and Barnaba, Vincenzo},
title = {Transforming growth factor β induced as a novel secreted immune checkpoint counterinhibiting human tumor-associated T cells},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {4},
pages = {e012668},
doi = {10.1136/jitc-2025-012668}
}
EUVIMED